Dr. Dhupar focuses his research efforts on improving cancer care. His basic and translational interests include developing new applications for currently available drugs for esophageal cancer, geared towards clinical trials. Specifically, he is working on modulating the tumor microenvironment to improve response to chemotherapy, radiation therapy, and immunotherapy, including the newer class of checkpoint inhibitors (PD-1/PD-L1/CTLA-4 antibodies). This research has potential to significantly impact the treatment of esophageal cancer. His lab is located in the Hillman Cancer Center, in the center for DAMP (Danger Associated Molecular Patterns) Biology.
He also has interests in health care disparities, with a goal of improving access and outcomes for patients with thoracic malignancies